非霍奇金淋巴瘤放射免疫治疗的涅槃重生:核医学的凤凰?
本文回顾了B细胞非霍奇金淋巴瘤放射免疫治疗(RIT)的兴衰:抗CD20 RIT药物Zevalin®和Bexxar®分别于2002年和2003年获FDA批准,但Bexxar®因商业需求有限于2014年撤市,Zevalin®近年供应极为有限,I-131利妥昔单抗仅在澳大利亚、印度等国有限使用。作者提出,鉴于当前PSMA和SSTR靶向放射性药物在肿瘤治疗中的巨大临床与商业兴趣,NHL的RIT能否像凤凰一样以更优形态从灰烬中重生。
要点
- 抗CD20 RIT药物Zevalin®和Bexxar®分别于2002年和2003年获FDA批准用于NHL治疗。
- Bexxar®因商业需求有限于2014年撤市,Zevalin®近年供应极为有限。
- I-131利妥昔单抗仅在澳大利亚、印度等国有限使用。
核心结论
- 作者提出,鉴于当前PSMA和SSTR靶向放射性药物在肿瘤治疗中的巨大临床与商业兴趣,NHL的RIT能否像凤凰一样从灰烬中以更优形态重生。
研究设计与样本
- 本文为综述,未报告系统检索范围。
主要发现
- 抗CD20 RIT药物Zevalin®和Bexxar®分别于2002年和2003年获FDA批准作为NHL安全有效的疗法。
- Bexxar®虽具治疗疗效,但于2014年因商业需求有限被生产商撤市,Zevalin®近年供应极为有限甚至无供应。
- I-131利妥昔单抗在澳大利亚、印度及其他国家有限使用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In Greek mythology, The Phoenix is an immortal bird that dies, but then achieves new life by rising from the ashes of its predecessor. Radioimmunotherapy (RIT) of B-cell Non-Hodgkin lymphoma (NHL) is a field which once began to fly high-with FDA approval of the anti-CD20 RITs Zevalin® and Bexxar® in 2002 and 2003 respectively, as safe and effective therapies of NHL. However, despite their therapeutic efficacy, Bexxar® was withdrawn from the market by the manufacturer in 2014 due to limited commercial demand and Zevalin® has had very limited to no availability of late. I-131 rituximab is used to a limited extent in Australia, India and other countries, as well. But has RIT of NHL been (perhaps prematurely) left for dead by many? Given the current great clinical and commercial interest in radiopharmaceutical therapies of cancer, notably PSMA and SSTR targeting agents in prostate and neuroendocrine cancers, can radioimmunotherapy of NHL-like the mythical Phoenix-now rise from its ashes in an even better form to fly higher, faster, farther and longer than before?
引用
- Wahl RL, Kahl B. The Rebirth of Radioimmunotherapy of Non-Hodgkin Lymphoma: The Phoenix of Nuclear Medicine? Semin Nucl Med. 2024. PMID: 39019652. doi:10.1053/j.semnuclmed.2024.06.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。